Search

Your search keyword '"Proudfoot, J.A."' showing total 10 results
Start Over Author "Proudfoot, J.A."
10 results on '"Proudfoot, J.A."'

1. Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)

Author

Pra, A. Dal, primary, Zwahlen, D.R., additional, Liu, V.Y., additional, Hayoz, S., additional, Spratt, D.E., additional, Davicioni, E., additional, Liu, Y., additional, Proudfoot, J.A., additional, Schär, C., additional, Hölscher, T., additional, Gut, P., additional, Polat, B., additional, Hildebrandt, G., additional, Mueller, A.C., additional, Plasswilm, L., additional, Feng, F.Y., additional, Pollack, A., additional, Thalmann, G., additional, Aebersold, D.M., additional, and Ghadjar, P., additional

Published
2022
Full Text
View/download PDF

2. 1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials

Author

Nguyen, P., primary, Liu, V., additional, Proudfoot, J.A., additional, Davicioni, E., additional, Liu, Y., additional, Dal Pra, A., additional, Spratt, D.E., additional, Sandler, H.M., additional, Efstathiou, J.A., additional, Lawton, C., additional, Simko, J.P., additional, Rosenthal, S., additional, Zeitzer, K., additional, Mendez, L., additional, Hartford, A., additional, Hall, W., additional, Desai, A., additional, Pugh, S., additional, Tran, P.T., additional, and Feng, F., additional

Published
2022
Full Text
View/download PDF

5. 1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

Author

Parry, M., Grist, E., Brawley, C., Proudfoot, J.A., Mendes, L., Lall, S., Hoyle, A.P., Sachdeva, A., Liu, Y., Amos, C., Sydes, M.R., Jones, R., Parmar, M.K., Feng, F., Sweeney, C.J., Clarke, N., Davicioni, E., James, N.D., L. Brown, and Attard, G.

Published
2022
Full Text
View/download PDF

6. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases

Author

Martin, C.F., Kappelman, M.D., Proudfoot, J.A., Nguyen, N.H., Jain, A., Sandborn, W.J., Long, M.D., and Singh, S.

Abstract

INTRODUCTION:We conducted a cohort study on the impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) measures in the inflammatory bowel disease (IBD) Partners cohort.METHODS:We performed a cross-sectional and longitudinal study within IBD Partners, an internet-based cohort of >15,000 patients living with Crohn's disease (CD) and ulcerative colitis (UC). We included adult patients with IBD, with recorded body mass index (BMI), with at least 6 months of follow-up, excluding patients with BMI < 18.5 kg/m2. We evaluated the independent effect of World Health Organization classes of obesity on risk of clinical relapse or persistent disease activity (using validated disease activity indexes) and PROMIS measures, using multivariate logistic regression and linear regression, respectively.RESULTS:We included 7,296 patients with IBD (4,748 patients with CD, 19.5% obese; 2,548 patients with UC with intact colon, 20.3% obese). Obesity was independently, and in a dose-dependent fashion, associated with an increased risk of persistent disease activity or relapse in both patients with CD (class II or III obesity vs normal BMI: adjusted odds ratio, 1.86; 95% confidence interval, 1.30-2.68) and UC (adjusted odds ratio, 2.97; 95% confidence interval, 1.75-5.17). Obesity was also independently associated with higher anxiety, depression, fatigue, pain, and inferior social function scores in patients with CD and UC at baseline and with worsening depression, fatigue, pain, and social function in patients with CD on longitudinal assessment.DISCUSSION:Obesity at baseline is independently associated with worsening disease activity and PROMIS measures in patients with IBD.

Published
2019
Full Text
View/download PDF

9. Implementation of a clinical guideline to decrease laboratory tests in newborns evaluated for early onset sepsis.

Author

Le, C.N., Sauer, C.W., Law, C., Proudfoot, J.A., and Song, R.S.

Subjects
NEONATAL sepsis, CHORIOAMNIONITIS, SEPSIS, BLOOD cell count, INTENSIVE care units, NEONATAL intensive care, LENGTH of stay in hospitals
Abstract

BACKGROUND: Creation of a clinical guideline to reduce the number of complete blood counts (CBCs) obtained on healthy term infants for early onset sepsis (EOS) evaluation secondary to maternal chorioamnionitis. METHODS: A clinical guideline was introduced at four neonatal intensive care units (NICU) to reduce laboratory tests during EOS evaluation. Measures include frequency and timing of CBCs, culture negative sepsis, length of stay, and readmission rate. RESULTS: Mean number of CBCs per patient significantly decreased (2.31±0.62 versus 1.52±0.65) without increasing trends for patients with culture negative sepsis, length of stay, or re-admission. CONCLUSION: The clinical guideline demonstrated a significant reduction in the number of CBCs obtained in well-appearing infants admitted to the NICU secondary to maternal chorioamnionitis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results